|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2008
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
1 WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, 3 Hygiene and Preventive Medicine Institute, University of Sassari, Sassari, 7 E. Morelli Hospital, Reference Hospital for MDR and HIV TB, Sondalo, 8 National Institute for Infectious Diseases, L. Spallanzani, Rome, 10 Fondazione S. Maugeri, Care and Research Institute, Cassano delle Murge, 11 University of Foggia, Foggia, and 12 Emerging Bacterial Pathogens Unit, S. Raffaele Scientific Institute, Milano, Italy, 2 Division of Clinical Infectious Diseases, Medical Clinic, Research Centre Borstel, Borstel, 4 Dept of Medicine, Parsberg Hospital, Parsberg, and 5 Supranational Reference Laboratory of Tuberculosis, IML Asklepios Clinic Munich-Gauting, Munich-Gauting, Germany, 6 University of Tartu, Tartu, Estonia, 9 TB Program, PATH, Seattle, WA, USA, 13 For a full list of the members of the TBNET Study Group, please refer to the Acknowledgements section.
CORRESPONDENCE: G. B. Migliori, WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, via Roncaccio 16, 21049, Tradate, Italy. Fax: 39 331829402. E-mail: giovannibattista.migliori{at}fsm.it
Keywords: Drug resistance, extensively drug-resistant tuberculosis, injectable second-line drugs, multidrug-resistant tuberculosis, tuberculosis
Received: February 25, 2008
Accepted March 14, 2008
No information is currently available on the influence of injectable second-line drugs on treatment outcomes of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) patients.
To investigate this issue, a large series of MDR- and XDR-TB cases diagnosed in Estonia, Germany, Italy and the Russian Federation (Archangels Oblast) between 1999 and 2006 were analysed. All study sites performed drug susceptibility testing for first- and second-line anti-TB drugs, laboratory quality assurance and treatment delivery according to World Health Organization recommendations.
Out of 4,583 culture-confirmed cases, 240 MDR- and 48 XDR-TB cases had a definitive outcome recorded (treatment success, death, failure). Among MDR- and XDR-TB cases, capreomycin resistance yielded a higher proportion of failure and death than capreomycin-susceptible cases. Resistance to capreomycin was independently associated with unfavourable outcome (logistic regression analysis: odds ratio 3.51).
In the treatment of patients with multidrug-resistant and extensively drug-resistant tuberculosis, resistance to the injectable drug capreomycin was an independent predictor for therapy failure in this cohort. As Mycobacterium tuberculosis drug resistance is increasing worldwide, there is an urgent need for novel interventions in the fight against tuberculosis.
This article has been cited by other articles:
|
|
 |
|
  G. B. Migliori, G. Sotgiu, M. D'Arcy Richardson, R. Centis, A. Facchini, G. Guenther, A. Spanevello, C. Lange, and for TBNET MDR-TB and XDR-TB: drug resistance and treatment outcomes Eur. Respir. J., September 1, 2009; 34(3): 778 - 779. [Full Text] [PDF]
|
|
|
|
|
|
A. K. Khurana and P. R. Mohapatra To the Editors: Eur. Respir. J., September 1, 2009; 34(3): 780 - 780. [Full Text] [PDF]
|
|
|
|
|
|
G. B. Migliori, B. Eker, M. D. Richardson, G. Sotgiu, J-P. Zellweger, A. Skrahina, J. Ortmann, E. Girardi, H. Hoffmann, G. Besozzi, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis Eur. Respir. J., August 1, 2009; 34(2): 387 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Blasi, R. Cosentini, G. B. Migliori, and W. Boersma Steps forward in LRTI and tuberculosis: update from the ERS Respiratory Infections Assembly Eur. Respir. J., June 1, 2009; 33(6): 1448 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Abubakar, J Moore, F Drobniewski, M Kruijshaar, T Brown, M Yates, C Anderson, E G Smith, J Magee, M Lipman, et al. Extensively drug-resistant tuberculosis in the UK: 1995 to 2007 Thorax, June 1, 2009; 64(6): 512 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kliiman and A. Altraja Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Eur. Respir. J., May 1, 2009; 33(5): 1085 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sotgiu, G. Ferrara, A. Matteelli, M. D. Richardson, R. Centis, S. Ruesch-Gerdes, O. Toungoussova, J-P. Zellweger, A. Spanevello, D. Cirillo, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET Eur. Respir. J., April 1, 2009; 33(4): 871 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Hwang, H-R. Kim, H. J. Kim, M. J. Kim, S. M. Lee, C-G. Yoo, Y. W. Kim, S. K. Han, Y-S. Shim, and J-J. Yim Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Eur. Respir. J., March 1, 2009; 33(3): 581 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Yew and C. C. Leung Update in Tuberculosis 2008 Am. J. Respir. Crit. Care Med., March 1, 2009; 179(5): 337 - 343. [Full Text] [PDF]
|
|
|
|
|
|
G. B. Migliori, M. D. Richardson, and C. Lange Of Blind Men and Elephants: Making Sense of Extensively Drug-resistant Tuberculosis Am. J. Respir. Crit. Care Med., November 15, 2008; 178(10): 1000 - 1001. [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Shah, R. Pratt, L. Armstrong, V. Robison, K. G. Castro, and J. P. Cegielski Extensively Drug-Resistant Tuberculosis in the United States, 1993-2007 JAMA, November 12, 2008; 300(18): 2153 - 2160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Caminero Extensively drug-resistant tuberculosis: is its definition correct? Eur. Respir. J., November 1, 2008; 32(5): 1413 - 1415. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |